Secondary prevention of myocardial infarction: impact of clinical trials on clinical practice.
作者信息
Rumboldt Z, Bozić I, Sardelić S
出版信息
Eur J Clin Pharmacol. 1995;48(3-4):311-2. doi: 10.1007/BF00198319.
PMID:7589062
Abstract
摘要
相似文献
1
Secondary prevention of myocardial infarction: impact of clinical trials on clinical practice.心肌梗死的二级预防：临床试验对临床实践的影响。
Eur J Clin Pharmacol. 1995;48(3-4):311-2. doi: 10.1007/BF00198319.
2
Therapeutic interventions in acute myocardial infarction. Survey of the ACCP Section on Clinical Cardiology.急性心肌梗死的治疗干预措施。美国胸科医师学会临床心脏病学分会调查
Chest. 1984 Aug;86(2):257-62. doi: 10.1378/chest.86.2.257.
3
Clinical trials versus clinical practice in the secondary prevention of myocardial infarction.心肌梗死二级预防中的临床试验与临床实践
Eur J Clin Pharmacol. 1994;46(2):95-9. doi: 10.1007/BF00199869.
4
The golden hours of the myocardial infarction: nonthrombolytic interventions.心肌梗死的黄金救治时间：非溶栓干预措施
Ann Emerg Med. 1991 May;20(5):540-8. doi: 10.1016/s0196-0644(05)81612-9.
5
[Secondary prevention after myocardial infarction].[心肌梗死后的二级预防]
Kardiologiia. 1993;33(4):72-9.
6
Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators.心血管药物的随机临床试验结果会影响医学实践吗？心肌梗死存活研究（SAVE）调查组。
N Engl J Med. 1992 Jul 23;327(4):241-7. doi: 10.1056/NEJM199207233270405.
7
Secondary prevention after myocardial infarction. Too many choices, which ones work?心肌梗死后的二级预防。选择太多，哪些有效呢？
Arch Intern Med. 1993 Feb 8;153(3):285-8.
8
9
Myocardial infarction.心肌梗死
Clin Evid. 2006 Jun(15):140-63.
10
Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction.设计和/或实施随机试验的医生与从事常规临床实践的医生在急性心肌梗死药物治疗使用方面的趋势：MILIS-TIMI研究经验。梗死面积限制多中心调查。心肌梗死溶栓治疗。
Am Heart J. 1999 Jan;137(1):79-92. doi: 10.1016/s0002-8703(99)70462-x.
引用本文的文献
1
Is aspirin underused in myocardial infarction?阿司匹林在心肌梗死中是否未得到充分使用？
Pharmacoeconomics. 1997 Nov;12(5):524-32. doi: 10.2165/00019053-199712050-00003.
本文引用的文献
1
Clinical trials versus clinical practice in the secondary prevention of myocardial infarction.心肌梗死二级预防中的临床试验与临床实践
Eur J Clin Pharmacol. 1994;46(2):95-9. doi: 10.1007/BF00199869.
2
Drug utilization data in risk/benefit analyses of drugs--benefit analysis.药物风险/效益分析中的药物利用数据——效益分析
Acta Med Scand Suppl. 1984;683:141-7. doi: 10.1111/j.0954-6820.1984.tb08730.x.
Zotero 插件